Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

All Germall

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1077-2016
Class II · Moderate risk

All TRIE Products

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1071-2016
Class III · Low risk

Oxygen

CGMP Deviations: Cylinders filled using out of date gauges.

Terminated cGMP deviation Medical Park Homecare, Inc D-0776-2016
Class II · Moderate risk

Oxygen

cGMP Deviations; trailer may not have met GMP requirements prior to filling

Terminated cGMP deviation AGA Gas Inc NDC 33237-001-01 D-0779-2016
Class II · Moderate risk

Repaskin 30

cGMP Deviations; product does not comply with cGMP requirements

Ongoing cGMP deviation Sesderma, SL NDC 63181-0010-1 D-0849-2016
Class II · Moderate risk

Repaskin 50

cGMP Deviations; product does not comply with cGMP requirements

Ongoing cGMP deviation Sesderma, SL NDC 63181-0011-1 D-0848-2016
Class II · Moderate risk

Repaskin 30

cGMP Deviations; product does not comply with cGMP requirements

Ongoing cGMP deviation Sesderma, SL NDC 63181-0012-1 D-0845-2016
Class II · Moderate risk

Repaskin 50

cGMP Deviations; product does not comply with cGMP requirements

Ongoing cGMP deviation Sesderma, SL NDC 63181-0013-1 D-0844-2016
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4299-31 D-0012-2016
Class III · Low risk

FUROSEMIDE Tablets USP

CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.

Terminated cGMP deviation Boehringer Ingelheim Roxane Inc NDC 0054-4297-31 D-0011-2016
Class III · Low risk

UN1002 Air

CGMP Deviations: Confirmed customer compliant of odor when turning on a cylinder of medical air.

Terminated cGMP deviation Praxair Inc. D-0783-2016